Novo Nordisk Unveils Wegovy Heart Rhythm Data at ESC 2025

Novo Nordisk said it will present new clinical and real-world data on its GLP-1 medicines Wegovy, Ozempic and the oral formulation Rybelsus during the European Society of Cardiology Congress (ESC 2025) later this month. The company highlighted that one analysis will examine Wegovy’s impact on atrial fibrillation, while additional studies will detail cardiometabolic benefits of Ozempic and Rybelsus in people living with type 2 diabetes. The forthcoming data come as demand for GLP-1 therapies continues to reshape global diabetes and obesity treatment. In the United Kingdom, health authorities are preparing a major overhaul of market-access rules that would give earlier priority to GLP-1 and SGLT-2 drugs, and a survey of 121 large U.S. employers projects that spending on GLP-1s, cancer care and mental-health services will help push employer health-care costs up by a median 9% in 2026.